Harshani Green
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Harshani Green has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
A. Carver
1 shared publicationA. Chaturvedi
1 shared publicationA. Ward
University College London Hospitals NHS Foundation Trust, London, UK
1 shared publication- Alexandra Taylor
Department of Clinical Oncology, The Royal Marsden Foundation Trust , London, SW3 6JJ
1 shared publication - Andre Dekker
Department of Radiation Oncology (Maastro), GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands
1 shared publication - Anthony Lighterness
Clinical Outcomes and Data Unit, The Christie NHS Foundation Trust, Manchester, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 17 December 2024
- Published by Elsevier in Clinical Oncology
- Vol. 39, 103732
Best Practice for Patient-centred Radiotherapy in Clinical Trials and Beyond—A National Multidisciplinary Consensus
- 17 December 2024
- Published by Elsevier in Clinical Oncology
- Vol. 39, 103732
Open AccessBest Practice for Patient-centred Radiotherapy in Clinical Trials and Beyond—A National Multidisciplinary Consensus
- Open Access
- 18 November 2024
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 6
Challenges and opportunities for real-world evidence in clinical oncology—a view from the UK: proceedings of a national workshop
- 18 November 2024
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 6
Open AccessChallenges and opportunities for real-world evidence in clinical oncology—a view from the UK: proceedings of a national workshop
- Open Access
Beyond the Knife in Renal Cell Carcinoma: A Systematic Review—To Ablate or Not to Ablate?
Intensified systemic therapy in metastatic renal cell carcinoma (mRCC) has led to improved patient outcomes. Patients commonly require local control of one or a few metastases. The aim was to evaluate metastasis-directed ablative therapies in extracranial mRCC. Two databases and one registry were searched, using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) approach, for all prospective and matched-pair case–control mRCC studies of radiofrequency ablation (RFA), cryotherapy, microwave ablation (MWA), and stereotactic body radiotherapy (SBRT). Eighteen studies were identified. Fourteen investigated SBRT in 424 patients. Four thermal ablation studies were identified: two cryotherapy (56 patients) and two RFA studies (90 patients). The median participant number was 30 (range 12–69). The combined median follow-up was 17.3 months (range 8–52). Four SBRT studies reported local control (LC) at 12 months, median 84.4% (range 82.5–93). Seven studies (six SBRT and one cryotherapy) reported an LC rate of median 87% (79–100%). Median overall survival (OS) was reported in eight studies (five SBRT, two cryotherapy, and one RFA) with a median of 22.7 months (range 6.7–not reached). Median progression-free survival was reported in seven studies (five SBRT, one cryotherapy, and one RFA); the median was 9.3 months (range 3.0–22.7 months). Grade ≥ 3 toxicity ranged from 1.7% to 10%. SBRT has excellent local control outcomes and acceptable toxicity. Only four eligible thermal ablative studies were identified and could not be compared with SBRT. Translationally rich definitive studies are warranted.
Open AccessBeyond the Knife in Renal Cell Carcinoma: A Systematic Review—To Ablate or Not to Ablate?
Intensified systemic therapy in metastatic renal cell carcinoma (mRCC) has led to improved patient outcomes. Patients commonly require local control of one or a few metastases. The aim was to evaluate metastasis-directed ablative therapies in extracranial mRCC. Two databases and one registry were searched, using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) approach, for all prospective and matched-pair case–control mRCC studies of radiofrequency ablation (RFA), cryotherapy, microwave ablation (MWA), and stereotactic body radiotherapy (SBRT). Eighteen studies were identified. Fourteen investigated SBRT in 424 patients. Four thermal ablation studies were identified: two cryotherapy (56 patients) and two RFA studies (90 patients). The median participant number was 30 (range 12–69). The combined median follow-up was 17.3 months (range 8–52). Four SBRT studies reported local control (LC) at 12 months, median 84.4% (range 82.5–93). Seven studies (six SBRT and one cryotherapy) reported an LC rate of median 87% (79–100%). Median overall survival (OS) was reported in eight studies (five SBRT, two cryotherapy, and one RFA) with a median of 22.7 months (range 6.7–not reached). Median progression-free survival was reported in seven studies (five SBRT, one cryotherapy, and one RFA); the median was 9.3 months (range 3.0–22.7 months). Grade ≥ 3 toxicity ranged from 1.7% to 10%. SBRT has excellent local control outcomes and acceptable toxicity. Only four eligible thermal ablative studies were identified and could not be compared with SBRT. Translationally rich definitive studies are warranted.
- 6 January 2022
- Published by Elsevier in Clinical Oncology
- Vol. 34 (7) , e281-e290
Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma – a Role in Patients with Para-aortic Lymph Node Involvement? A 10-year Institutional Experience
- 6 January 2022
- Published by Elsevier in Clinical Oncology
- Vol. 34 (7) , e281-e290
Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma – a Role in Patients with Para-aortic Lymph Node Involvement? A 10-year Institutional Experience